Arena Pharmaceuticals Investor Relations Material

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company offers BELVIQ, a serotonin 2C receptor agonist approved for marketing in the United States; Belviq XR, an extended-release formulation of lorcaserin; APD334 that is in phase II clinical study for treating autoimmune diseases, including ulcerative colitis and Crohn's disease; APD371 for the treatment of patients with pain associated with Crohn's disease; and APD811, which is in phase I clinical stage to treat pulmonary arterial hypertension. It also develops ralinepag (APD811), which has completed phase II clinical stage for the treatment of pulmonary arterial hypertension.